These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 3858013)
1. Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro. Hill BT; Dennis LY; Li XT; Whelan RD Cancer Chemother Pharmacol; 1985; 14(3):194-201. PubMed ID: 3858013 [TBL] [Abstract][Full Text] [Related]
2. Cellular uptake and efflux and cytostatic activity of 4'-O-tetrahydropyranyladriamycin in adriamycin-sensitive and resistant tumor cell lines. Kunimoto S; Miura K; Umezawa K; Xu CZ; Masuda T; Takeuchi T; Umezawa H J Antibiot (Tokyo); 1984 Dec; 37(12):1697-702. PubMed ID: 6526737 [TBL] [Abstract][Full Text] [Related]
3. Activity of (7) anthracycline related compounds in an doxorubicin sensitive human small cell lung cancer line and its doxorubicin resistant descendant. Activity of doxorubicin, daunorubicin, 4-deoxyrubicin, 4-demethoxydaunorubicin, detorubicin, 4'-epidoxorubicin and mitoxantrone. Zijlstra JG; Meijer C; Timmer-Bosscha H; Le TK; de Vries EG; Mulder NH Eur J Respir Dis Suppl; 1987; 149():53-5. PubMed ID: 3034649 [No Abstract] [Full Text] [Related]
4. Selective interactions of verapamil with anthraquinones in adriamycin-sensitive and -resistant murine and human tumour cell lines in vitro. Gibby EM; Boyse O; Hill BT Cancer Chemother Pharmacol; 1987; 20(1):5-7. PubMed ID: 3621454 [TBL] [Abstract][Full Text] [Related]
5. In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia. Johnson RK; Chitnis MP; Embrey WM; Gregory EB Cancer Treat Rep; 1978 Oct; 62(10):1535-47. PubMed ID: 709555 [TBL] [Abstract][Full Text] [Related]
6. 9-alkyl anthracyclines. Absence of cross-resistance to adriamycin in human and murine cell cultures. Scott CA; Westmacott D; Broadhurst MJ; Thomas GJ; Hall MJ Br J Cancer; 1986 May; 53(5):595-600. PubMed ID: 3718817 [TBL] [Abstract][Full Text] [Related]
8. Comparative toxicity of mitoxantrone and doxorubicin on hematopoietic stem cells. OKunewick JP; Buffo MJ; Kociban DL Exp Hematol; 1985; 13 Suppl 16():23-30. PubMed ID: 3987836 [TBL] [Abstract][Full Text] [Related]
9. In vitro circumvention of anthracycline--resistance in Ehrlich ascites tumour by anthracycline analogues. Friche E; Jensen PB; Roed H; Skovsgaard T; Nissen NI Biochem Pharmacol; 1990 Jun; 39(11):1721-6. PubMed ID: 2344368 [TBL] [Abstract][Full Text] [Related]
10. Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of daunorubicin and doxorubicin in HL60 and its resistant cells and comparison with those of pirarubicin. Nagasawa K; Natazuka T; Nomiyama M; Ohnishi N; Yokoyama T Biol Pharm Bull; 1996 Jan; 19(1):100-5. PubMed ID: 8820920 [TBL] [Abstract][Full Text] [Related]
11. [Establishment of adriamycin-resistant human small-cell lung cancer cells in culture: analysis of the mechanism of resistance and cross-resistance]. Kimura I; Ohnoshi T; Hiraki S; Miyamoto H Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):830-6. PubMed ID: 3032107 [TBL] [Abstract][Full Text] [Related]
12. Transport mechanisms of anthracycline derivatives in human leukemia cell lines: uptake of pirarubicin, daunorubicin and doxorubicin by K562 and multidrug-resistant K562/ADM cells. Nagasawa K; Takara K; Nomiyama M; Ohnishi N; Yokoyama T Biol Pharm Bull; 1996 Jul; 19(7):971-6. PubMed ID: 8839972 [TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of dihydroxyanthraquinone and adriamycin on the survival of cultured Chinese hamster cells. Kimler BF; Cheng CC Cancer Res; 1982 Sep; 42(9):3631-6. PubMed ID: 7105035 [TBL] [Abstract][Full Text] [Related]
14. Intracellular glutathione as a determinant of responsiveness to antitumor drugs. Romine MT; Kessel D Biochem Pharmacol; 1986 Oct; 35(19):3323-6. PubMed ID: 3464280 [TBL] [Abstract][Full Text] [Related]
15. Anthracycline resistance in P388 murine leukemia and its circumvention by calcium antagonists. Kessel D; Wilberding C Cancer Res; 1985 Apr; 45(4):1687-91. PubMed ID: 3919944 [TBL] [Abstract][Full Text] [Related]
16. Resistance to anthrapyrazoles and anthracyclines in multidrug-resistant P388 murine leukemia cells: reversal by calcium blockers and calmodulin antagonists. Klohs WD; Steinkampf RW; Havlick MJ; Jackson RC Cancer Res; 1986 Sep; 46(9):4352-6. PubMed ID: 3460695 [TBL] [Abstract][Full Text] [Related]
17. Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line. Son YS; Suh JM; Ahn SH; Kim JC; Yi JY; Hur KC; Hong WS; Muller MT; Chung IK Cancer Chemother Pharmacol; 1998; 41(5):353-60. PubMed ID: 9523730 [TBL] [Abstract][Full Text] [Related]
18. [Studies on the mechanism of drug resistance in tumor cells and a new antitumor antibiotic]. Tanaka N Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2666-73. PubMed ID: 6210060 [TBL] [Abstract][Full Text] [Related]
19. Comparative in vitro activity of 4'-deoxy-4'-iododoxorubicin and other anthracyclines in the human tumor clonogenic assay. Schwartz JE; Salmon SE Invest New Drugs; 1987; 5(3):231-4. PubMed ID: 3478322 [TBL] [Abstract][Full Text] [Related]
20. [New anthracycline antibiotics and derivatives]. Tatsuta K Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2640-52. PubMed ID: 6594977 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]